Specifications TableSubject areaBiologyMore specific subject areaPharmacology, PainType of dataFigureHow data was acquiredBehavioral testing in animals with manual quantification. LC-20AC HPLC system coupled to a triple quad 6500 + mass spectrometer (HPLC-QqQ-MS) equipped with a Turbo V ion source (AB Sciex, Singapore) was used for pharmacokinetics. Analyst™ 1.7.1 software (Applied Biosystems, Foster City, CA) was applied to data collection, processing, and analysis.Data formatRaw and analyzedExperimental factorsThe blood microdialysis probe is with 4 mm effective membrane length; 20,000 molecular weight cut-off and was positioned within the jugular vein toward the right atrium and then perfused with anti-coagulant citrate dextrose solution consisting of citric acid 3.5 mM, sodium citrate 7.5 mM, and dextrose 13.6 mM. The brain microdialysis probe was implanted in the corpus striatum zone and perfused with Ringer\'s solution (consisting of NaCl 145.3 mM; KCl 4.01mM; CaCl2 2.97 mM; pH 7.0) at 1.5 μl/min.Experimental featuresFor assessment of potential side effects, the total travel distance, number of rearing behaviors, the duration of passivity and rectal temperature were recorded.Data source locationBeijing, China.Data accessibilityThe data was attached with this article.Related research articleT. Gao, T. Shi, Z. Wiesenfeld-Hallin, T. Li, J.-D. Jiang, X.- J. Xu, 2019. Sinomenine facilitates the efficacy of gabapentin or ligustrazine hydrochloride in animal models of neuropathic pain. Eur. J. Pharmacol., 854,101--108. [https://doi.org/10.1016/j.ejphar.2019.03.061](10.1016/j.ejphar.2019.03.061){#intref0010} \[[@bib1]\].**Value of the Data**• Data presented in this article is helpful for understanding the potential side effects of sinomenine plus gabapentin or ligustrazine hydrochloride in animals.• Data presented in this article could provide pharmacokinetic insights of sinomenine in plasma and CNS tissue after intravenous injection.• Data presented in this article could be used to understand the underlying mechanisms of sinomenine drug combinations in chronic pain management.

1. Data {#sec1}
=======

In our earlier published data, the repeated drug administration of sinomenine 10mg/kg plus gabapentin 4mg/kg reduced baseline hypersensitivity, and resulted in persistent reduction in allodynia with increased baseline thresholds \[[@bib1]\]. Here we report experimental data on if there were severe side effects accompanying drug applications of sinomenine plus gabapentin or ligustrazine hydrochloride that could affect the rodent\'s behaviors, or severe allergy that could result in the reduction of body temperature. Shown in [Fig. 1](#fig1){ref-type="fig"} ([Table 1 in Raw Dataset](#appsec1){ref-type="sec"}), duration of passivity ([Fig. 1](#fig1){ref-type="fig"}A), locomotion (moved distance, [Fig. 1](#fig1){ref-type="fig"}B), numbers of rearing behaviors ([Fig. 1](#fig1){ref-type="fig"}C), and rectal temperatures ([Fig. 1](#fig1){ref-type="fig"}D) were recorded after applications of drug combinations and compared with naïve mice. We have earlier discovered after repeated administration of sinomenine plus gabapentin, the baseline pain threshold was increased \[[@bib1]\]. We know that the interchange of gabapentin between blood and CNS tissue is occurring at an extremely fast speed, however there is lack of relevant data for the interchange rate of sinomenine between blood and CNS tissue, to understand whether sinomenine could be accumulated in CNS tissue at pharmacologically active doses and intervals. To explain if the increased baseline pain threshold under repeated administration of sinomenine plus gabapentin \[[@bib1]\] is associated with accumulation of sinomenine, we acquired additional data ([Fig. 2](#fig2){ref-type="fig"}, [Table 2 in Raw Dataset](#appsec1){ref-type="sec"}). Using microdialysis technique, Data in [Fig. 2](#fig2){ref-type="fig"} illustrated the changes of sinomenine concentration in CNS tissue ([Fig. 2](#fig2){ref-type="fig"}A) and plasma ([Fig. 2](#fig2){ref-type="fig"}B) after single or repeated injections. Post-drug concentrations of sinomenine in CNS tissue followed similar trend under single or repeated injections in rats ([Fig. 2](#fig2){ref-type="fig"}A), which provided evidence that the increased baseline drug efficacy seen in our earlier published data \[[@bib1]\] was unlikely due to an accumulation of the drug following repeated injections.Fig. 1To investigate whether sinomenine (SN) combined with gabapentin (GBP) or ligustrazine hydrochloride (LZH) could generate noticeable adverse effects, mice were i.p. treated with "SN20mg/kg + GBP15mg/kg", or "SN20mg/kg + LZH20mg/kg", duration of passivity (A), locomotion (moved distance, B), numbers of rearing behaviors (C), and rectal temperatures (D) were quantified and compared with naïve mice without any pharmacological or vehicle treatment. N = 6 mice for each group. Data was presented as Mean ± SEM. One-Way ANOVA indicated that there were no significant differences between the groups. No significant differences were detected between naïve and drug-treated mice. No sign of tissue edema or sustained itch was discovered in association with drug application.Fig. 1Fig. 2To study if pharmacokinetics of sinominine (SN) in plasma and brain share similar characteristics, we continuously collected samples (using microdialysis), and detected SN concentrations in striatum of the brain (extracellular levels, A) and the blood (B). N = 2--3 rats for each group. Data was presented as Mean ± SEM. Following SN (50mg/kg, intravenous) single or repeated administrations (once per day for 3 days, detecting samples were collected after last injection at day 3). Under single SN administration, SN concentrations was higher in blood than in brain. Also, SN concentrations in blood and brain followed similar trend, which was illustrated by sharp reduction and almost completely cleared in around 6 h from 5150.65 ± 1212.09 (Mean ± SD) ng/ml at 0 h to 17.72 ± 12.53 (Mean ± SD) ng/ml at 6 h in plasma; and from 456.63 ± 88.48 (Mean ± SD) ng/ml at 0 h to 4.15 ± 2.07 (Mean ± SD) ng/ml at 6 h in extracellular striatal tissue; SN concentrations at 6 h in plasma or extracellular striatal tissue are considered as ultralow levels). Following repeated SN administration, SN concentrations resembled the trend of the single dose application (green square versus black circle, A), with SN concentrations sharply reduced from 397.17 ± 61.97 (Mean ± SD) ng/ml at 0 h to 49.79 ± 40.01 (Mean ± SD) ng/ml at 6 h in extracellular striatal tissue. The data showed that sinomenine could be cleared in around 6 h after drug application, and even there is uncleared drugs remained before first drug application at each day, the concentrations should be at ultralow level. There is no chance to generate drug accumulation of SN by repeated dosing especially in the targeted tissue (Brian), which is confirmed by testing SN\'s brain concentration under repeated dosages (A). The elevated baseline discovered in our pharmacological study \[[@bib1]\], is more likely to be related to the pharmacodynamics effects than pharmacokinetics effects of the repeated drug combination.Fig. 2

2. Experimental design, materials and methods {#sec2}
=============================================

2.1. Experimental design {#sec2.1}
------------------------

Previously we have found sinomenine can be used for the treatment of chronic pain in animal models \[[@bib2], [@bib3], [@bib4]\]. Recently, we were able to show that there are additional benefits by combining sinomenine with gabapentin or ligustrazine chloride in treating neuropathic pain situation \[[@bib1]\]. In order to support this finding and show that there were no noticeable side effects accompanying drug applications of sinomenine plus gabapentin or ligustrazine hydrochloride, we performed open filed test in mice applied with above mentioned drug combinations, which was shown in data section in [Fig. 1](#fig1){ref-type="fig"}. To further give supportive data to understand whether the elevation of baseline pain threshold after repeated administration of sinomenine plus gabapentin, is related to accumulation of each drugs in CNS tissue, we performed additional tests using 2--3 rats with single or repeated (once per day for 3 days) intravenous injection of sinomenine at 50mg/kg, which could illustrate sinomenine\'s pharmacokinetics difference in plasma and in CNS tissue. This data was shown in [Fig. 2](#fig2){ref-type="fig"}. Detailed materials and methods of the presented data are mentioned below.

2.2. Animals {#sec2.2}
------------

All mice (C57BL/6, male, from Beijing Vital River Laboratory Animal Technology, China) or rats (SD, male, from Beijing Vital River Laboratory Animal Technology, China), background information for C57BL/6 mice and SD rats can be found in [Raw Dataset Table.3](#appsec1){ref-type="sec"}. Animals were age matched and the littermates were housed together in the same cage, with 6 per cage for mice or 4 per cage for rats respectively, in a standard laboratory condition (22 °C 12 h light/dark cycle) with ad libitum access to water and food. For [Fig. 1](#fig1){ref-type="fig"} and [Raw Dataset Table.1](#appsec1){ref-type="sec"}, "SN20mg/kg + GBP15mg/kg", "SN20mg/kg + LZH20mg/k" or "Naïve" group were comprised by randomly combining 2 mice from each of 3 age matched cages (6 mice per cage). For [Fig. 2](#fig2){ref-type="fig"} and [Raw Dataset Table.2](#appsec1){ref-type="sec"}, rats received single or repeated sinomenine injection were selected from 2 different age matched cages (4 rats per cage).

2.3. Assessment of side effects {#sec2.3}
-------------------------------

To assess if drug combinations induce motor deficiencies, sedation or change of body temperature in mice, we performed an open field test. The open field arena is 50 cm × 50 cm with 25 grids (the area of one grid is 10 cm × 10 cm), in which mice (without any previous experience in the open field test) were allowed to move freely for 5 min. As illustrated in our previous published study \[[@bib3]\], the total travel distance (quantified by the number of passed grids), number of rearing behaviors and duration of passivity (time when animal showed no movement) were recorded and quantified manually, and rectal temperature was recorded using a rodent thermometer (Bioseb, USA).

2.4. Pharmacokinetics study using microdialysis {#sec2.4}
-----------------------------------------------

Pharmacokinetics study using microdialysis was performed in SD rats. The blood microdialysis probe (4 mm effective membrane length; 20,000 molecular weight cut-off; CMA Microdialysis, Sweden) was positioned within the jugular vein toward the right atrium and then perfused with anti-coagulant citrate dextrose solution consisting of citric acid 3.5 mM, sodium citrate 7.5 mM, and dextrose 13.6 mM. The brain microdialysis probe was implanted in the corpus striatum zone and perfused with Ringer\'s solution (consisting of NaCl 145.3 mM; KCl 4.01mM; CaCl2 2.97 mM; pH 7.0) at 1.5 μl/min after a stabilization period of 1 h post probe implantation. After intravenous drug administration of sinomenine at 50 mg/kg, simultaneous collection of microdialysis samples in blood and striatum of brain were performed at different time points (20 min/sample, collecting for at least 6 h). An established high performance liquid chromatography coupled with triple quadrupole mass spectrometry method \[[@bib5]\], was deployed for detection of sinomenine concentrations, and the results were corrected with in vitro recovery of the probe.

2.5. Drugs {#sec2.5}
----------

For preparation of sinomenine injection solution, sinomenine (CAS No. 6080-33-7, Catalog No. 110774, obtained from the National Institute for Food and Drug Control, Beijing, China, purity \>99%) was dissolved in DMSO (CAS No. 67-68-5, Catalog No. 34869, obtained from Sigma-Aldrich, Germany, purity \>99%), then mixed with Cremophor EL oil (CAS No. 61791-12-6, Catalog No. 238470, Sigma-Aldrich, Germany) and saline by vortex mixer (Bibby Scientific, UK) using the volume rate of 1:4:5. Any further dilution was mixed with saline (CAS No. 7647-14-5, Catalog No. S0817, obtained from Sigma-Aldrich, Germany). For preparation of gabapentin injection solution, gabapentin (CAS No. 60142-96-3, Catalog No. 1287303, obtained from obtained from Sigma-Aldrich Research Biochemicals Inc., USA) was dissolved in saline. Vehicle for gabapentin was saline solution. For preparation of ligustrazine hydrochloride injection solution, ligustrazine hydrochloride (CAS No. 76494-51-4, Catalog No. 3628, Sinova Inc., USA) was dissolved in saline.

2.6. Blinding {#sec2.6}
-------------

For experiment data in [Fig. 1](#fig1){ref-type="fig"} and [Raw Dataset Table.1](#appsec1){ref-type="sec"}, drugs are blinded by introducing Drug Codes (labeled by one person who does not perform the actual experiment), and decoded after data analysis. However, for experiment data in [Fig. 2](#fig2){ref-type="fig"} and [Raw Dataset Table.2](#appsec1){ref-type="sec"}, blinding was not used since there is only one condition/group for single or repeated drug application scheme.

2.7. Statistics {#sec2.7}
---------------

Data were presented as mean ± SEM. Bonferroni post hoc test following One-Way ANOVA were used to analyze the difference between groups, P \< 0.05 was considered as statistically significant ([Fig. 1](#fig1){ref-type="fig"}, [Raw Dataset Table.2](#appsec1){ref-type="sec"}). For [Fig. 2](#fig2){ref-type="fig"} and [Raw Dataset Table.2](#appsec1){ref-type="sec"}, considering that it is an exploratory approach to investigate the pharmacokinetics of single and repeatedly injected sinomenine, with only 2 to 3 animals per group, power analysis was not used.

Institutional review board statement for ethics in animal study {#sec3}
===============================================================
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